in vitro News and Research

RSS

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Researchers examine effects of curcumin on HNSCC growths

Curcumin, the compound that gives curry powder its yellow/orange color, may inhibit the adverse effects of nicotine in patients with head and neck cancer who continue to smoke.

4 Oct 2009

Retinoic acid may provide relief for ulcerative colitis

Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases.

3 Oct 2009

Diamedix files a 510(k) premarket submission with the FDA for its Mago4S assay system

IVAX Diagnostics, Inc. announced today that its U.S. subsidiary headquartered in Florida, Diamedix Corporation, has filed a 510(k) premarket submission with the U.S. Food and Drug Administration (“FDA”) for its next -generation fully automated Enzyme-linked Immunosorbent Assay (“ELISA”) system for autoimmune and infectious disease testing, named the Mago®4S.

1 Oct 2009

Incept BioSystems commences human clinical trial of its SMART Embryo Culture System

Incept BioSystems, Inc., a privately-held biomedical device company using patented microfluidic technology developed at the University of Michigan, announced today that it has initiated the first U.S. human clinical trial of its proprietary SMART Embryo Culture System. The microscale SMART technology platform is designed to improve the in vitro manipulation, performance, and viability of embryos for the treatment of patients undergoing in vitro fertilization (IVF).

1 Oct 2009

Grants to research GanedenBC30 probotic effect on human immune cells

Ganeden Biotech Inc., makers of the patented probiotic strain GanedenBC30® (Bacillus coagulans GBI-30, 6086), today announced two grants for early investigators.

1 Oct 2009

New treatment for Alzheimer's disease may be in the offing

Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.

30 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

Computational models form basis to design the device for recreating kidney function

Researchers from Mount Sinai School of Medicine and two other academic institutions have received federal funding to systematically assemble functional human kidney tissue from tissue modeled on a computer. If successful, the research-which ties together several emerging technologies including virtual tissue modeling and nanofabrication-could lead to a more predictable way for researchers to engineer tissue outside the body and, consequently, to screen for new drugs.

24 Sep 2009

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new ReninSense680(TM) FAST imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo.

24 Sep 2009

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

As part of an effort to develop effective medical therapies that block the progression of liver cyst growth in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), researchers at the University of Colorado Anschutz Medical Center have found that the liver cyst walls develop and maintain a vasculature as they grow out from the body of the liver and that factors released by epithelial cells that line the liver cyst wall lumen can drive the proliferation and development of vascular endothelial cells.

24 Sep 2009

Golden nanotubes detect tumor cells, map sentinel lymph nodes

Biomedical researchers at the University of Arkansas in Fayetteville and the University of Arkansas for Medical Sciences (UAMS) in Little Rock have developed a special contrast-imaging agent made of gold-coated carbon nanotubes that is capable of molecular mapping of lymphatic endothelial cells and detecting cancer metastasis in sentinel lymph nodes.

23 Sep 2009

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

Small pieces of nucleic acid known as short interfering RNAs, or siRNAs, can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials.

23 Sep 2009

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system -- the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX.

23 Sep 2009

Utah medical ethics expert chairs NIH review of embryonic cells

University of Utah medical ethics expert Jeffrey R. Botkin will chair a federal panel that will review scientists' requests to conduct government-funded research using embryonic stem cells left over from couples who used "test-tube fertilization" to have babies.

23 Sep 2009

Preclinical data on Protalix Biotherapeutics' antiTNF released

Protalix Biotherapeutics, Inc., reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel). Produced using the Company’s proprietary ProCellEx technology, pr-antiTNF is a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody IgG1 domain. Pr-antiTNF has an identical amino acid sequence to Enbrel.

23 Sep 2009

AMRI's new research & development facility dedicated by Governor Christine Gregoire

AMRI (NASDAQ:AMRI) executives were joined by Governor Christine Gregoire in dedicating the company’s new research & development facility located in Bothell, WA. The company leased 44,000 square feet at 22215 26th Avenue SE with an option on an additional 40,000 square feet through Arden Realty, Inc. and invested approximately $8 million in fit-out costs and equipment.

23 Sep 2009

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reported today that it has signed a “Master Service Agreement” with the Southern Research Institute (“Southern Research”), Birmingham, AL. Southern Research is a well established, prestigious institution that has performed preclinical testing services for several vaccines and antivirals.

21 Sep 2009

China Medical Technologies approves share repurchase program

China Medical Technologies, Inc. (the "Company"), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that its board of directors (the "Board") approved a share repurchase program on September 17, 2009.

18 Sep 2009

in vitro News and Research

Preclinical study results of AVL-181 protease inhibitor presented

Researchers examine effects of curcumin on HNSCC growths

Retinoic acid may provide relief for ulcerative colitis

Diamedix files a 510(k) premarket submission with the FDA for its Mago4S assay system

Incept BioSystems commences human clinical trial of its SMART Embryo Culture System

Grants to research GanedenBC30 probotic effect on human immune cells

New treatment for Alzheimer's disease may be in the offing

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

Computational models form basis to design the device for recreating kidney function

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

Golden nanotubes detect tumor cells, map sentinel lymph nodes

Magnetic nanoworms and nanocrystals deliver siRNA to tumors

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

Utah medical ethics expert chairs NIH review of embryonic cells

Preclinical data on Protalix Biotherapeutics' antiTNF released

AMRI's new research & development facility dedicated by Governor Christine Gregoire

Nanoviricides and Southern Research sign agreement to test anti-Influenza and anti-HIV drug candidates

China Medical Technologies approves share repurchase program

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News